Darin Latimer Email & Phone Number

Aurora, On, Ca

Washington, District Of Columbia, Us

Expanded responsibility within Corporate Strategic Development team, continuing focus on the three vectors:1) Scouting, due diligence, and integration for Mergers and Acquisitions o A key member of due diligence and/or integration including Abcam ($5.7B, 2023), Aldevron ($9.6B, 2021), Cytiva ($21B, 2020), Integrated DNA Technologies ($2B, 2018).2) Development, piloting and training of Strategic Planning tools and processes. o Facilitate and drive improvements for strategic planning training of Operating Company Presidents and their direct reports. These are at least annual cadence and bring to bear a comprehensive set of Strategic Planning and Danaher Business System (DBS) tools.3) Strategic Innovation for growth and sustainable competitive advantage o Development of proprietary strategic frameworks, insights and processes and connecting these to operational realization. Significant collaborative engagement with DBS Office members through pretotype, prototype, pilot, deploy and sustain phases.o Champion and co-developer of Open Innovation capability. Developing competencies with gap-Want-Find-Get-Manage approach integrated with DBS and existing business systems, now standard as SPG.o Facilitator for several kaizen events per year. Advanced Certified Practitioner and Certified Practitioner in DBS tools.

Washington, District Of Columbia, Us

Focused on three strategic vectors within in a small, dynamic Corporate Strategic Development team having enterprise wide remit:1) Scouting, due diligence, and integration for Mergers and Acquisitions o A key member of due diligence and/or integration including Cepheid ($4B, 2016), Pall ($14B, 2015), Beckman Coulter ($7B, 2011), MDS Analytical Technologies ($1B, 2009)2) Development, piloting and training of Strategic Planning tools and processes o Developed Technology Roadmapping as a strategic business capability connecting market needs and barriers with technologies, including the temporal evolution. o Drive continuous improvement of IP Landscaping and IP Strategy as business capabilities. 3) Strategic Innovation for growth and sustainable competitive advantage o Co-development of proprietary enterprise scaled systems - Innovation model used in strategic planning, M&A and product development. - Holistic view of innovation framework, tools, processes, environment. - Tools for Innovation and Growth (e.g. P2P, SIR) improving the connection between strategic planning and operational excellence.

Washington, District Of Columbia, Us

MDS Analytical Technologies was sold to Danaher Corporation, now Danaher operating companies AB Sciex (Concord headquarters) and Molecular Devices (Sunnyvale headquarters)Member of Strategy and Business Development team where I was primarily responsible for Science, Technology, IP aspects.

Active in advancing the field of innovation management within the ecosystem of global members in public and private-sector companies and federally funded laboratories.

Active Board member including evaluation of strategic options leading to IRI merger with The National Association of Manufacturers.IRI Board of Directors formally reorganized as Board of Advisors within NAM effective Jan 2022.

This committee supports and prioritizes projects to solve complex/thorny innovation management problems shared by membership. Approaches include an IRI developed proess, Research on Research (ROR). General framework is to connect members facing the same challenge, select and use the appropriate tools for the problem, create a deliverable for organizational leverage.

San Francisco, Ca, Us

The Manufacturing Customer Advisory Board helps drive/influence Autodesk product roadmaps. It is comprised of rotating membership of executives from select large global customers.

Member of Strategy and Business Development group where I was primarily responsible for Science, Technology, IP aspects.Managed MDS Analytical Technologies Legal group globally for a year up to and including the close of sale to the Danaher Corporation (~ $1.1B in total). I was point person for MDS AT IP matters within MDS AT. MDS Inc. Legal led legal activities for MDS Analytical Technologies transaction. This was a complicated transaction involving extracting from two parents (LIFE and MDS), two joint ventures (MDS/LIFE and MDS/PKI), and spining out a business segment (previously Arcturus business in Molecular Devices) to comply with FTC.

Directed instrument research activities in collaboration with Principal Scientists and other experts. Liason with Marketing, Product Development, Quality Assurance, and Manufacturing.Led Business Development capabilitiesLed Accelerated Programs in Product Development with emphaisis on speeding key capabilities to market. Advocate for new platform inititative.

Principal with responsibility for multidisciplinary team supporting genomics and proteomics programs including integration of commercial systems and custom hardware and software. Co-founded company and secured $5 million in initial funding through negotiations and due diligence processes. Secured $28 million in series B funding to accelerate development of proteomics platform and market genomics platform.

Designed, tested and utilized microarray based “molecular beacons” for detection of mutations in human tissue samples. Initial application in early detection of breast cancer.

Start-up medical device company based upon unique technology for shaping electromagnetic fields with applications including acute and chronic pain relief, portable MRI, and many others. Active in refining business plan and raising venture capital in addition to scientific responsibilities.

Us

Led research, development and integration of optical, electrical, mechanical, software, and safety subsystems. Involved in three major grants from NIH and NIST (ATP).Led multidisciplinary group of scientists and engineers in areas of instrumentation, molecular biological methods, automation and robotics, process engineering, microfabrication and machining. Developed instrument and data analysis systems (Niagara & OGI) from concept to production scale implementation in less than 18 months (>$1 Million project, grew group to about 10 people in process). Successful Niagara and OGI programs were instrumental in company’s initial public offering (NASDAQ:CRGN).

Ithaca, Ny, Us

Research in atmospherically important chemistry with emphasis on ozone reactions. Involved development of integrated chemical, optical and electronic systems. Leadership role and training of graduate students.

Calgary, Alberta, Ca

Summers.Member of a team developing high power density thermoelectric materials, primarily for military applications. Experience in metallurgical analysis, high temperature metal reactions, powder metals processing, instrumentation, high security projects.

Phd, Chemistry (Chemical Physics)

M.Sc., Chemistry

B.Sc., Chemistry (Physics/Engineering Physics Minor)